August 25, 2008 - Anthill Technologies, Inc. announced that it has entered into an agreement with Zafgen, Inc. to apply its high-speed chemistry technologies and capabilities to Zafgen’s obesity program. Zafgen, Inc. is a Boston-based biopharmaceutical company which develops obesity therapy based on the vascular targeting of adipose tissue.Under the agreement, Anthill will use its ACOS™ high-speed synthesis and on-demand purification capabilities to assist Zafgen in the development of lead compounds for its obesity therapy programs...
Anthill Technologies' Press Release -
